IDC PlanScape: Measuring and Scaling the ROI on Decentralized Clinical Trials for the Life Science Industry
This IDC PlanScape addresses the growing importance of decentralized clinical trials (DCTs), provides insights on the benefits and challenges associated with DCTs, identifies the key stakeholders involved, and provides guidance to the life science industry on how to choose the right partners and which are the critical key performance indicators (KPIs) that should be monitored to optimize the return on investment."Decentralized clinical trials are reshaping the life science industry. As organizations are rapidly attempting to transition from a 'pilotitis' mode to an enterprisewide implementation strategy, they need to take cognizance of the importance of defining key performance indicators, which will serve as measures of success through their DCT journey. The life science industry needs to develop a 'DCT Organizational Maturity Score' for DCT implementation, akin to a capability maturity model (CMM), which will help organizations to benchmark their performance, against themselves and against the industry," says Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy and Technology at IDC Health Insights.
Please Note: Extended description available upon request.
- IDC PlanScape Figure
- Executive Summary
- Why Is the DCT Model Important?
- What Is the DCT Model?
- Who Are the Key Stakeholders?
- How Can My Organization Take Advantage of the DCT Model?
- Building Out a Strategy to Optimize the ROI on DCTS
- Advice for Technology Buyers
- Related Research
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook